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Immune checkpoint inhibitors in non-small-cell lung cancer: 
key to long-term survival?
Since the first approval of immune checkpoint inhibitors 
(ICIs) for non-small-cell lung cancer in 2015, the 
treatment landscape of metastatic non-small-cell lung 
cancer has changed completely. At this point, three 
programmed death-ligand 1 (PD-[L]1) inhibitors are 
approved for stage 4 non-small-cell lung cancer, in 
first line (pembrolizumab) and beyond (nivolumab, 
pembrolizumab, atezolizumab). All trials showed sig-
nifi cantly improved overall survival compared with 
chemotherapy; the plateau in survival curves suggests 
long-term benefit. This resulted in rapid implementation 
of ICIs in daily practice. However, not all patients benefit 
from ICI because in several trials survival curves crossed 
and, although grade greater than or equal to 3 toxicity is 
lower for monotherapy ICI than chemotherapy, ICI can 
cause diverse and late toxicity, even after discontinuation.1
As long-term data on overall survival and toxicity 
are largely lacking, results of the single arm phase 1 
KEYNOTE-001 study by Natasha Leighl and colleagues,2 
accompanying this Comment, are of interest: they could 
help to improve selection of patients for ICI treatment.
Pembrolizumab (different doses and schedules) was 
investigated in 550 patients with non-small-cell lung 
cancer (101 previously untreated, 449 previously treated). 
Most (82%) had a PD-L1 tumour proportion score (TPS) 
greater than or equal to 1%: TPS was less than 1% in 
12 (12%) of patients who were previously untreated 
and 90 (20%) of patients who were previously treated. 
The study was first published in 2015,3 and the authors 
are to be applauded for providing the long-term overall 
survival data. With an updated median (minimum) 
follow-up of 34·5 (25·7) months, the estimated 3-year 
survival was 26·4% in previously untreated patients 
and 19·0% in previously treated patients, it was highest 
in those with a PD-L1 TPS of greater than or equal to 50% 
(25·2% in previously untreated and 29·7% in previously 
treated patients). 12% experienced grade 3–5 treatment 
related adverse events (TRAE), mostly within the first 
year of treatment and no late (ie, between years 2 and 3) 
grade 3-5 TRAEs were observed.
How do these data compare with other non-small-
cell lung cancer ICI studies with long-term follow-up 
available? Other data come from the phase 2–3 
KEYNOTE-010 (pembrolizumab versus docetaxel),4 the 
phase 1 CA209-003 (nivolumab),5 a pooled analysis of the 
phase 3 CheckMate-017 and CheckMate-057 (nivolumab 
vs docetaxel),6 and the phase 2 POPLAR trial (atezolizumab 
vs docetaxel).7 A difference between the KEYNOTE-001 
and the others is that only the KEYNOTE-001 trial also 
included previously untreated patients.
All these trials show that approximately one-fifth 
(17–23%) of the patients treated with ICI have long-
term benefit. Who are they and is it possible to select 
these patients beforehand? Nearly all long-term 
survivors had at least a partial response to ICI, with most 
responses occurring in the first months of treatment. 
Those with a high PD-L1 expression had the highest 
survival prevalence, but also some patients with low 
or negative PD-L1 levels survived 3 years or more. Data 
regarding the effect of tumour histology on survival 
in previously treated patients are conflicting, as in the 
KEYNOTE-001 trial, those with squamous histology had 
the longest survival, whereas in the POPLAR study the 
opposite was found. In KEYNOTE-010, CA209-003, and 
CheckMate-017–CheckMate-057, no differences were 
found. In contrast to the previously reported subgroup 
analysis of the KEYNOTE-001 trial (single institution, 
n=98),8 in this updated analysis, previous radiotherapy 
was not associated with improved survival. In general, 
those with an EGFR-mutation or ALK-rearrangement 
benefit less from ICI than those without.9 As is clear 
from the KEYNOTE-001 and the other trials, additional 
predictive factors for long-term ICI benefit should be 
evaluated.
Regarding toxicity in all the trials above, percentage 
TRAE grade 3–5 was similar (10–19%) and most of the 
grade 3–5 toxicity occurred in the first year or even the 
first months of treatment. This is an important finding 
for physicians, and underlines why especially in the first 
months of ICI treatment, close monitoring is advised. 
However, patients and physicians should be aware 
that, although rare, toxicity can occur late or even after 
discontinuation of ICI.
Another important question is the duration of ICI 
treatment. In the KEYNOTE-001 trial, patients with 
a complete response could discontinue treatment 
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after 6 months, and those with a partial response or 
stable disease could discontinue after 24 months. 
Interestingly, 35 (73%) of 48 patients chose to continue 
pembrolizumab. Information on subsequent progression 
or rechallenge pembrolizumab was not provided. In 
the KEYNOTE-010 trial, 79 (12%) of 682 patients 
completed 2 years of pembrolizumab. 25 (32%) of 
79 progressed off-pembrolizumab, 13 were retreated, 
and 6 (46%) of 13 responded. These results suggest 
that most responding patients completing 2 years of ICI 
can safely discontinue ICI. Is it possible to discontinue 
earlier? On the basis of the CheckMate-153 trial, 
discontinuing treatment on completion of 1-year 
nivolumab (regardless of response) is inferior compared 
with continuing nivolumab.10 The question remains 
whether a shorter treatment time is possible in those 
with a complete response. Furthermore, the role of 
discontinuing ICI on PET metabolic response,11 or a lower 
ICI dose or longer interval between cycles in responding 
patients is unclear and should be evaluated further.
In conclusion, monotherapy with ICI provides 
promising 3-year overall survival data in both previously 
untreated and previously treated patients with locally 
advanced or metastatic non-small-cell lung cancer, 
being most prevalent in responders and patients with a 
high PD-L1 TPS score.
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Burnout in women intensivists: a hidden epidemic?
Although the number of women entering medical 
training worldwide has largely reached parity with that of 
men, gender disparities remain, and fewer women than 
men are employed as intensivists worldwide. Inadequate 
gender parity in the intensive care workforce might 
adversely affect organisational diversity and can have 
unintended ramifications on collaboration and collective 
intelligence.1 Efforts to attract and retain a more balanced 
workforce of women and men intensivists could pay large 
dividends by impacting important metrics such as quality 
of care, career satisfaction, and physician retention. These 
metrics are all adversely affected by burnout syndrome.2 
The effects of burnout might be magnified in the 
intensive care unit (ICU) context, where attrition of the 
clinical workforce can pose a serious financial burden to 
health-care systems.3
Burnout develops insidiously. Although symptoms are 
generally not present early in employment, over time, 
affected individuals gradually develop emotional stress, 
disillusionment in their roles, increasing inability to 
adapt, and excessively negative work-related attitudes. 
Burnout syndrome is characterised by emotional 
exhaustion, being unable to find meaning in work, 
feelings of ineffectiveness, depersonalisation, and a 
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